title: [The toxicity of busulphan and cyclophosphamide as the preparative regimen for allogeneic peripheral blood stem cell transplantation].
abstract: OBJECTIVE
  To analyse the treatment-related complications of busulphan and cyclophosphamide (BU-CY) as the conditioning regimen for allogeneic peripheral blood stem cell transplantation (allo-PBSCT).
  
  
  METHODS
  The clinical data of 40 leukemia patients undergoing allo-PBSCT between June 1997 and May 1999 in our BMT center were retrospectively analysed.
  
  
  RESULTS
  Recovery of neutrophil and platelet was achieved at a median of day +13 (9 - 28) and day +12 (7 - 60) respectively. Acute GVHD occurred in 17 of 40 patients (42.5%) with grade II-IV in 10 patients (25%). Chronic GVHD developed in 21 out of 30 evaluable patients (70%). Mild to severe mucositis occurred in 30 patients (75%), and 4 of them had severe esophagitis with bleeding. Haemorrhagic cystitis developed in 8/40 (20%) patients, the median time of its onset was day +100 (+7 to +165). Six of 40 patients (15%) developed interstitial pneumonia (IP), 5 of them were due to cytomegalovirus infection, and the remaining one due to pneumocystis carinii infection. No hepatic veno-occlusive disease was observed and no seizure occurred. During the median follow-up of 480 (300 - 1000) days, 4 (10%) patients relapsed and 8 (20%) patients died of the transplant-related complications. The 3 year leukemia-free survival rate was 70%.
  
  
  CONCLUSIONS
  BU (domestic busulfan)-CY regimen is relatively easy to administer and well tolerated, with low extramedullary toxicities.
authors.affiliation: Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou 310009, China.
authors.forename: K
authors.initials: K
authors.lastname: Zhu
authors.forename: Y
authors.initials: Y
authors.lastname: Xu
authors.forename: D
authors.initials: D
authors.lastname: Wu
authors.forename: X
authors.initials: X
authors.lastname: Xu
authors.forename: L
authors.initials: L
authors.lastname: Huang
mesh_terms: D000208:Acute Disease; D000328:Adult; D002066:Busulfan / Q000009:adverse effects* / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D003556:Cystitis / Q000209:etiology; D018572:Disease-Free Survival; D004941:Esophagitis / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009061:Mouth Mucosa / Q000187:drug effects / Q000473:pathology; D013280:Stomatitis / Q000209:etiology; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D002066:Busulfan